{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:45:02Z","timestamp":1790844302971,"version":"4.1.0"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T00:00:00Z","timestamp":1683590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Chronic lymphocytic leukemia (CLL) cells are metabolically flexible and adapt to modern anticancer treatments. Bruton tyrosine kinase (BTK) and B-cell lymphoma-2 (BCL-2) inhibitors have been widely used to treat CLL, but CLL cells become resistant to these treatments over time. CB-839 is a small-molecule glutaminase-1 (GLS-1) inhibitor that impairs glutamine use, disrupts downstream energy metabolism, and impedes the elimination of reactive oxygen species.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      To investigate the\n                      <jats:italic>in vitro<\/jats:italic>\n                      effects of CB-839 on CLL cells, we tested CB-839 alone and in combination with ibrutinib, venetoclax, or AZD-5991 on the HG-3 and MEC-1 CLL cell lines and on primary CLL lymphocytes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We found that CB-839 caused dose-dependent decreases in GLS-1 activity and glutathione synthesis. CB-839\u2013treated cells also showed increased mitochondrial superoxide metabolism and impaired energy metabolism, which were reflected in decreases in the oxygen consumption rate and depletion of the adenosine triphosphate pool and led to the inhibition of cell proliferation. In the cell lines, CB-839 combined with venetoclax or AZD-5991, but not with ibrutinib, demonstrated synergism with an increased apoptosis rate and cell proliferation inhibition. In the primary lymphocytes, no significant effects of CB-839 alone or in combination with venetoclax, ibrutinib, or AZD-5991 were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Our findings suggest that CB-839 has limited efficacy in CLL treatment and shows limited synergy in combination with widely used CLL drugs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2023.1161254","type":"journal-article","created":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T01:32:25Z","timestamp":1683595945000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":32,"title":["Preclinical investigations of the efficacy of the glutaminase inhibitor CB-839 alone and in combinations in chronic lymphocytic leukemia"],"prefix":"10.3389","volume":"13","author":[{"given":"Natalia","family":"Timofeeva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary L.","family":"Ayres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Baran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice M.","family":"Santiago-O\u2019Farrill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gamze","family":"Bildik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Konopleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varsha","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.Mcr-17-0026","article-title":"B-cell receptor signaling regulates metabolism in chronic lymphocytic leukemia","volume":"15","author":"Vangapandu","year":"2017","journal-title":"Mol Cancer Res"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-532200","article-title":"Mitochondrial metabolism contributes to oxidative stress and reveals therapeutic targets in chronic lymphocytic leukemia","volume":"123","author":"Jitschin","year":"2014","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25166","article-title":"Biological and metabolic effects of iacs-010759, an oxphos inhibitor, on chronic lymphocytic leukemia cells","volume":"9","author":"Vangapandu","year":"2018","journal-title":"Oncotarget"},{"key":"B4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41408-017-0039-2","article-title":"Del11q-positive cll lymphocytes exhibit altered glutamine metabolism and differential response to Gls1 and glucose metabolism inhibition","volume":"8","author":"Galicia-V\u00e1zquez","year":"2018","journal-title":"Blood Cancer J"},{"key":"B5","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.ccr.2012.02.014","article-title":"Metabolic reprogramming: a cancer hallmark even warburg did not anticipate","volume":"21","author":"Ward","year":"2012","journal-title":"Cancer Cell"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-05-1699","article-title":"Cell death of bioenergetically compromised and transcriptionally challenged cll lymphocytes by chlorinated atp","volume":"105","author":"Balakrishnan","year":"2005","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/msb.2013.65","article-title":"Glutamine-driven oxidative phosphorylation is a major atp source in transformed mammalian cells in both normoxia and hypoxia","volume":"9","author":"Fan","year":"2013","journal-title":"Mol Syst Biol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jss.2005.07.013","article-title":"Stressing out over survival: glutamine as an apoptotic modulator","volume":"131","author":"Fuchs","year":"2006","journal-title":"J Surg Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2011.12.009","article-title":"Glucose-independent glutamine metabolism Via tca cycling for proliferation and survival in b cells","volume":"15","author":"Le","year":"2012","journal-title":"Cell Metab"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-621870","article-title":"Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with bcl-2 inhibition","volume":"126","author":"Jacque","year":"2015","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12944","article-title":"Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected aml subtypes","volume":"7","author":"Matre","year":"2016","journal-title":"Oncotarget"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1004594107","article-title":"The bruton tyrosine kinase inhibitor pci-32765 blocks b-cell activation and is efficacious in models of autoimmune disease and b-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1006\/geno.1997.4747","article-title":"Cloning and gene mapping of the chromosome 13q14 region deleted in chronic lymphocytic leukemia","volume":"42","author":"Kalachikov","year":"1997","journal-title":"Genomics"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s001090050350","article-title":"Chromosome aberrations in b-cell chronic lymphocytic leukemia: reassessment based on molecular cytogenetic analysis","volume":"77","author":"D\u00f6hner","year":"1999","journal-title":"J Mol Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0800121105","article-title":"Mir-15a and mir-16-1 cluster functions in human leukemia","volume":"105","author":"Calin","year":"2008","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2017.159","article-title":"Bcl2 and mir-15\/16: from gene discovery to treatment","volume":"25","author":"Pekarsky","year":"2018","journal-title":"Cell Death Differ"},{"key":"B17","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ccell.2019.08.005","article-title":"Mitochondrial reprogramming underlies resistance to bcl-2 inhibition in lymphoid malignancies","volume":"36","author":"Gui\u00e8ze","year":"2019","journal-title":"Cancer Cell"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau1167","article-title":"Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma","volume":"11","author":"Zhang","year":"2019","journal-title":"Sci Transl Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00411","article-title":"Ibrutinib resistance is reduced by an inhibitor of fatty acid oxidation in primary cll lymphocytes","volume":"8","author":"Galicia-V\u00e1zquez","year":"2018","journal-title":"Front Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA119.008180","article-title":"Dual inhibition of glutaminase and carnitine palmitoyltransferase decreases growth and migration of glutaminase inhibition-resistant triple-negative breast cancer cells","volume":"294","author":"Reis","year":"2019","journal-title":"J Biol Chem"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2020.12.038","article-title":"Glutaminase inhibition with telaglenastat (Cb-839) improves treatment response in combination with ionizing radiation in head and neck squamous cell carcinoma models","volume":"502","author":"Wicker","year":"2021","journal-title":"Cancer Lett"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0259241","article-title":"The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma","volume":"16","author":"Emberley","year":"2021","journal-title":"PloS One"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.Mct-21-0071","article-title":"Gilteritinib inhibits glutamine uptake and utilization in Flt3-Itd-Positive aml","volume":"20","author":"Zavorka Thomas","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.16262","article-title":"Glutaminase inhibitor Cb-839 synergizes with carfilzomib in resistant multiple myeloma cells","volume":"8","author":"Thompson","year":"2017","journal-title":"Oncotarget"},{"key":"B25","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1158\/1535-7163.Mct-13-0870","article-title":"Antitumor activity of the glutaminase inhibitor Cb-839 in triple-negative breast cancer","volume":"13","author":"Gross","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.4226.4226","article-title":"Antitumor activity of the glutaminase inhibitor Cb-839 in hematological malignances","volume":"122","author":"Parlati","year":"2013","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(98)00154-4","article-title":"Mec1 and Mec2: two new cell lines derived from b-chronic lymphocytic leukaemia in prolymphocytoid transformation","volume":"23","author":"Stacchini","year":"1999","journal-title":"Leukemia Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01614-0","article-title":"Novel mitochondria-targeting compounds selectively kill human leukemia cells","volume":"36","author":"Panina","year":"2022","journal-title":"Leukemia"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1038\/s41467-022-30396-3","article-title":"Inhibition of mitochondrial complex I reverses Notch1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia","volume":"13","author":"Baran","year":"2022","journal-title":"Nat Commun"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btw230","article-title":"Combenefit: an interactive platform for the analysis and visualization of drug combinations","volume":"32","author":"Di Veroli","year":"2016","journal-title":"Bioinformatics"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-09-1947","article-title":"Drug combination studies and their synergy quantification using the chou-talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","article-title":"Defining the role of mtor in cancer","volume":"12","author":"Guertin","year":"2007","journal-title":"Cancer Cell"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.4161\/cc.22632","article-title":"Glutaminolysis feeds Mtorc1","volume":"11","author":"Dur\u00e1n","year":"2012","journal-title":"Cell Cycle"},{"key":"B34","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41467-017-00369-y","article-title":"Glutamine metabolism regulates autophagy-dependent Mtorc1 reactivation during amino acid starvation","volume":"8","author":"Tan","year":"2017","journal-title":"Nat Commun"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2012.05.043","article-title":"Glutaminolysis activates rag-Mtorc1 signaling","volume":"47","author":"Dur\u00e1n","year":"2012","journal-title":"Mol Cell"},{"key":"B36","article-title":"Autophagy: a protective mechanism in response to stress and inflammation","volume":"7","author":"Heymann","year":"2006","journal-title":"Curr Opin Investig Drugs"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-18-0985","article-title":"Assessing metabolic intervention with a glutaminase inhibitor in real-time by hyperpolarized magnetic resonance in acute myeloid leukemia","volume":"18","author":"Zacharias","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01927-8","article-title":"Detection of early seeding of Richter transformation in chronic lymphocytic leukemia","volume":"28","author":"Nadeu","year":"2022","journal-title":"Nat Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1080\/10428190410001723317","article-title":"Role of myeloid cell factor-1 (Mcl-1) in chronic lymphocytic leukemia","volume":"45","author":"Johnston","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"B40","doi-asserted-by":"publisher","first-page":"pe17","DOI":"10.1126\/scisignal.2001959","article-title":"Atm is a redox sensor linking genome stability and carbon metabolism","volume":"4","author":"Kr\u00fcger","year":"2011","journal-title":"Sci Signal"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-020-0258-3","article-title":"A comparative pharmaco-metabolomic study of glutaminase inhibitors in glioma stem-like cells confirms biological effectiveness but reveals differences in target-specificity","volume":"6","author":"Koch","year":"2020","journal-title":"Cell Death Discovery"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.mito.2016.09.001","article-title":"Alterations of mitochondrial biogenesis in chronic lymphocytic leukemia cells with loss of P53","volume":"31","author":"Ogasawara","year":"2016","journal-title":"Mitochondrion"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.384","article-title":"The P53 family orchestrates the regulation of metabolism: physiological regulation and implications for cancer therapy","volume":"116","author":"Napoli","year":"2017","journal-title":"Br J Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1042\/bst0311337","article-title":"Kinetics of superoxide scavenging by glutathione: an evaluation of its role in the removal of mitochondrial superoxide","volume":"31","author":"Jones","year":"2003","journal-title":"Biochem Soc Trans"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3164\/jcbn.14-42","article-title":"A mitochondrial superoxide theory for oxidative stress diseases and aging","volume":"56","author":"Indo","year":"2015","journal-title":"J Clin Biochem Nutr"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.627837","article-title":"Mitochondrial reactive oxygen species and their contribution in chronic kidney disease progression through oxidative stress","volume":"12","author":"Tirichen","year":"2021","journal-title":"Front Physiol"},{"key":"B47","first-page":"8","article-title":"Glutathione","volume":"13","author":"Pizzorno","year":"2014","journal-title":"Integr Med (Encinitas)"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.2566.2566","article-title":"Phase 1 study of Cb-839, a first-in-Class, orally administered small molecule inhibitor of glutaminase in patients with Relapsed\/Refractory leukemia","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1182\/blood-2019-125970","article-title":"Interim analysis of a phase ii study of the glutaminase inhibitor telaglenastat (Cb-839) in combination with azacitidine in advanced myelodysplastic syndrome (Mds)","volume":"134","author":"Guerra","year":"2019","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.3059.3059","article-title":"Phase 1 study of Cb-839, a first-in-Class, glutaminase inhibitor in patients with multiple myeloma and lymphoma","volume":"126","author":"Vogl","year":"2015","journal-title":"Blood"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1161254\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T01:32:33Z","timestamp":1683595953000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1161254\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,9]]},"references-count":50,"alternative-id":["10.3389\/fonc.2023.1161254"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1161254","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,9]]},"article-number":"1161254"}}